Redwood Investments LLC Increases Stock Position in Enovis Co. (NYSE:ENOV)

Redwood Investments LLC increased its position in Enovis Co. (NYSE:ENOV - Free Report) by 39.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,043 shares of the company's stock after buying an additional 8,787 shares during the quarter. Redwood Investments LLC owned 0.05% of Enovis worth $1,362,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of ENOV. Quadrant Capital Group LLC lifted its position in Enovis by 53.0% during the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock valued at $30,000 after buying an additional 239 shares during the period. Amalgamated Bank boosted its holdings in shares of Enovis by 1.0% in the fourth quarter. Amalgamated Bank now owns 25,887 shares of the company's stock worth $1,136,000 after buying an additional 264 shares during the last quarter. Pinnacle Bancorp Inc. grew its holdings in Enovis by 54.5% during the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock valued at $37,000 after purchasing an additional 300 shares during the period. Arizona State Retirement System increased its stake in shares of Enovis by 2.6% in the fourth quarter. Arizona State Retirement System now owns 16,208 shares of the company's stock worth $711,000 after purchasing an additional 414 shares in the last quarter. Finally, UMB Bank n.a. raised its stake in Enovis by 128.2% during the 4th quarter. UMB Bank n.a. now owns 778 shares of the company's stock valued at $34,000 after purchasing an additional 437 shares during the period. 98.45% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Canaccord Genuity Group decreased their price objective on Enovis from $75.00 to $70.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Needham & Company LLC dropped their price objective on shares of Enovis from $64.00 to $57.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Finally, JMP Securities lowered their target price on shares of Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $58.00.

Enovis Price Performance

NYSE ENOV traded down $0.61 during mid-day trading on Tuesday, hitting $34.87. The stock had a trading volume of 230,612 shares, compared to its average volume of 1,011,702. Enovis Co. has a twelve month low of $29.32 and a twelve month high of $51.31. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The stock has a market capitalization of $1.99 billion, a price-to-earnings ratio of -15.92 and a beta of 1.79. The firm's 50 day moving average is $35.13 and its 200 day moving average is $41.37.

Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.07. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company had revenue of $558.83 million for the quarter, compared to analyst estimates of $558.80 million. During the same period in the prior year, the business earned $0.50 EPS. The firm's quarterly revenue was up 8.2% on a year-over-year basis. Equities research analysts forecast that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.